Enabling Dual Payload ADCs Incorporating Novel Payloads Through Innovative Linker Design
2:15 pm - Wednesday 29th July 2026
- Rationally engineering linker architectures to precisely tune payload-specific release kinetics, balancing plasma stability with efficient intracellular cleavage, thereby maximizing synergistic efficacy and overcoming heterogeneous tumour resistance
- Implementing technical improvements to achieve controlled, site-specific dual loading, enabling precise drug-to-antibody ratios while preventing payload exchange, stochastic distribution, or conjugation-site competition
- Developing integrated, high-throughput screening workflows to rapidly evaluate novel payload combinations, leveraging modular linker platforms, parallel conjugation strategies, and miniaturized in vitro cytotoxicity and stability assays to identify promising synergistic warhead pairings
